Highlight Capital

Highlight Capital is a venture capital firm based in Shanghai, China, founded in 2014. The firm is dedicated to supporting healthcare companies in achieving strong and sustained growth prospects within the Chinese market. Highlight Capital focuses on investing in various sectors, including healthcare services, biomedicine, medical technology, mobile healthcare, and pharmaceuticals. The firm aims to partner with entrepreneurs who demonstrate commitment and uphold high standards in their endeavors.

Zhao Gang

Founding Partner

Jenny Jiang

Executive Director

120 past transactions

Hongpu Technology

Seed Round in 2025
Hongpu Technology is a high-tech enterprise that independently develops high-end instruments and provides high-tech solutions.

Qianxun Intelligence

Seed Round in 2025
Qianxun Intelligence is an intelligent technology developer that offers software development, intelligent robot research and development, AI hardware sales, AI application software development, information system integration services, and Internet sales.

ZhongQing Robot

Seed Round in 2025
Zhongqing Robotics is a pioneering company specializing in the development of general-purpose intelligent robots. It focuses on comprehensive research and development, integrating collaborative software and hardware innovations to create full-stack robotic technology. The company aims to serve the broader robotics industry by providing cutting-edge, industry-specific solutions.

Methuselah Medical Technology

Series B in 2025
Methuselah is a medical nutrition technology company focused on the research, development, production, and sales of specialized nutrition products. The company offers a range of medical nutrition solutions tailored to the diverse needs of the Chinese population, emphasizing the importance of customized nutrition for different demographic groups. Its product lineup includes youkangli, youyili, yusu, yusupeptide, and qingliusu, as well as various food items such as biscuits, noodles, fiber composite powder, complex fiber meal replacement powder, fiber tea, and moon cakes. Methuselah collaborates with strategic partners, including one in the United States, to enhance its product offerings and ensure they meet the specific nutritional requirements of its clients.

Jiamai shares

Venture Round in 2025
Jiamai specializes in the manufacture of precision pneumatic components. It mainly develops and produces precision slide cylinders, pneumatic fingers, digital pressure sensors, and other pneumatic components. Their products are widely used in LCD, OLED, smartphones, lasers, lithium batteries, and other consumer electronics equipment.

Shengfang Technology

Series A in 2025
Shengfang Technology is a high-tech company that combines sales, service, production, and research and development for excimer lasers.

TOYA

Series C in 2024
TOYA specializes in the production of ultra-fine copper and copper alloy conductors.

Meditip Company

Series D in 2024
Meditip is a consulting company focused on healthcare licensing, offering expertise to navigate both domestic and global medical markets. The firm specializes in the development and commercialization of bioproducts and medical devices, providing services such as licensing, insurance, clinical support, aftercare, and distributor discovery. Through its extensive knowledge and experience, Meditip assists clients in making informed decisions and effectively entering the medical marketplace.

Sieran Medical

Seed Round in 2024
Sieran Medical is a medical device company that provides precise and intelligent minimally invasive surgical treatment solutions for ophthalmology.

ZhongQing Robot

Seed Round in 2024
Zhongqing Robotics is a pioneering company specializing in the development of general-purpose intelligent robots. It focuses on comprehensive research and development, integrating collaborative software and hardware innovations to create full-stack robotic technology. The company aims to serve the broader robotics industry by providing cutting-edge, industry-specific solutions.

ENGINEAI

Seed Round in 2024
ENGINEAI is committed to advancing the commercialization of humanoid robot technology worldwide.

Qianxun Intelligence

Seed Round in 2024
Qianxun Intelligence is an intelligent technology developer that offers software development, intelligent robot research and development, AI hardware sales, AI application software development, information system integration services, and Internet sales.

Wuxi Gongwang

Seed Round in 2024
Wuxi Gongwang inductive sensor developer offering high-precision, oil and dust-resistant products for various industries, including aerospace, automotive, medical care, and more.

MCT millimeter intelligence

Seed Round in 2024
MCT (Milli Intelligence) is an innovative company that specializes in intelligent space-time sensing chips and solutions. It is dedicated to providing top-tier products and services to consumers in autonomous driving, intelligent robotics, IoT, shared travel, digital twins, vertical industries, and other areas.

EdgeRock

Series A in 2024
EdgeRock offers an automotive integrated brake-by-wire system. EdgeRock supplies highly integrated capabilities for big and heavy load technologies.

Shifan Microelectronics

Seed Round in 2024
Shifan Microelectronics offers intelligent display SOC chip design and development services. Shifan Microelectronics is primarily concerned with the research and development of display processing and device technologies.

Hydropeng Technology

Seed Round in 2024
Hydropeng Technology is a company that developes solid oxide fuel cell specializes in the engineering development of solid oxide fuel cells (SOFC) and electrolytic cells (SOEC). Hydropeng Technology applies its extensive R&D capabilities in materials, chemistry, mechanics, and other fields to create efficient hydrogen energy systems that fulfill the green energy demands of global ESG development.

Aoli Biotechnology

Seed Round in 2024
Aoli Biotechnology is a biopharmaceutical oral delivery technology provider. Aoli Biotechnology focuses on research into macromolecule oral delivery technology and has developed a number of world-leading excipient technology patents, including soteria and phloral technology.

Tachem

Series A in 2023
Tachem is a biotechnology company that develops, produces, and distributes a range of products derived from the protected amino acid series. These products cater to diverse industries, including medical, healthcare, food, and cosmetics, serving as high-quality chemical raw materials and biotechnical solutions for various applications.

Hongce Precision

Seed Round in 2023
Hongce Precision specializes in wafer-level chip inspection, offering a range of solutions including probe cards and test boards. The company has independently developed these products, catering to diverse chip types such as panel driver chips, image sensors, and logic chips.

Stand Group

Series C in 2023
Stand Group provides diversified testing and R&D services to national and global markets in health, economic, and social development fields.

Viva Biotech

Post in 2023
Viva Biotech Holdings is a Shanghai-based company that specializes in structure-based drug discovery services for biotechnology and pharmaceutical clients worldwide. Founded in 2008, the company offers a comprehensive range of research and development services, including fragment-based drug discovery and advanced screening technologies such as affinity selection mass spectrometry and cryo-electron microscopy. Viva Biotech provides various products, including cell lines, crystal structures, GPCR proteins, and antibodies, alongside services in medicinal chemistry, in vitro pharmacology, and antibody discovery. The company operates as an integrated drug discovery platform, combining its expertise in early-stage drug research with contract development and manufacturing services for small molecule active pharmaceutical ingredients and intermediates. Its innovative approach and advanced technological platforms position Viva Biotech as a valuable partner in the global drug development landscape.

Acchrom

Series A in 2023
Acchrom, operating under Huapu Instrument (Beijing) Technology Co., Ltd., specializes in chromatographic separation products, offering comprehensive solutions that include equipment, consumables, software, and technical services. The company aims to establish itself as a leading national brand in chromatography by developing targeted marketing strategies and building a professional marketing network across key provinces. Acchrom's focus on the complete chromatography process enables clients to effectively analyze and separate mixtures, positioning the company as a significant player in the field.

Rgenta Therapeutics

Series A in 2023
Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

Tripod Preclinical Research

Funding Round in 2023
Tripod Preclinical Research is a Contract Research Organization that specializes in providing preclinical research services to the biopharmaceutical and medical device industries. The company offers a comprehensive range of services, including drug safety evaluation for new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Tripod's expertise encompasses non-human primate disease models, pharmacological efficacy studies, early drug evaluation, and Good Laboratory Practices (GLP) toxicology. Additionally, the organization supports translational medicine and clinical trials, along with biological analysis and the management of biological sample banks. By delivering these services, Tripod aids drug developers and researchers in advancing their projects through the critical early stages of research and development.

Hongyixin

Seed Round in 2023
Hongyixin is an automotive electronic chip developer.

Etana

Debt Financing in 2023
Etana is a biotechnology company dedicated to the production and sale of biopharmaceuticals, particularly focusing on oncology and other life-threatening diseases. The company specializes in the development and commercialization of biological drugs, including biosimilars, aimed at serving Indonesia and other emerging markets. Etana's operations encompass research and development, manufacturing, and marketing of advanced medical treatments, such as recombinant gene technology and monoclonal antibody drugs. By prioritizing affordability, Etana strives to provide patients with access to essential medicines and vaccines.

ProBio

Series C in 2023
ProBio Inc. is a one-stop biopharmaceutical R&D and production platform. It provides end-to-end services for cell and gene therapy drugs, vaccine and biopharmaceutical discovery, antibody protein drugs.

Base Therapeutics

Series A in 2023
Base Therapeutics is a biotechnology company focused on developing cell and gene editing technologies aimed at treating cancerous diseases. Its core innovation includes a natural killer cell genetic engineering platform, along with various cell therapy products specifically designed for the treatment of lung cancer, liver cancer, glioma, and other hematological tumors. By enhancing the safety and effectiveness of clinical applications of gene editing, Base Therapeutics aims to provide healthcare professionals with advanced therapeutic options for patients suffering from these challenging conditions.

LePure Biotech

Series C in 2023
Lechun Biology is an enterprise engaged in disposable products and leak detection equipment in the biotechnology and pharmaceutical industries. The company develops and produces disposable biopharmaceutical process equipment and consumables. The products are used for the storage, transportation, filling and leak detection of various samples in biosimilars, vaccines and other biopharmaceutical processes. The core product is a disposable storage bag. Recently completed B+ round of financing. This round of financing will be mainly used for the development of a number of innovative new products, the establishment of a US R&D center, the integration of the upstream industrial chain, the securing of the supply chain, and the expansion of the R&D market operation team at home and abroad.

Etana

Series B in 2022
Etana is a biotechnology company dedicated to the production and sale of biopharmaceuticals, particularly focusing on oncology and other life-threatening diseases. The company specializes in the development and commercialization of biological drugs, including biosimilars, aimed at serving Indonesia and other emerging markets. Etana's operations encompass research and development, manufacturing, and marketing of advanced medical treatments, such as recombinant gene technology and monoclonal antibody drugs. By prioritizing affordability, Etana strives to provide patients with access to essential medicines and vaccines.

Silicon Innovation

Seed Round in 2022
Silicon Innovation is a technology company based in Chengdu, China, specializing in interconnect chip solutions for the enterprise sector. Established in December 2019, the company focuses on the development of high-end analog and digital-analog hybrid chips, which cater to various applications including clocks, interfaces, and power management. Silicon Innovation's products support critical industries such as data centers, 5G communications, artificial intelligence, autonomous driving, intelligent monitoring, new energy vehicles, and the Internet of Things. By providing advanced chip solutions, the company enables businesses to enhance their systems and products across multiple sectors.

Bibost Automotive Electronics

Seed Round in 2022
Bebest Automotive Electronics specializes in the production and research of advanced automotive electronic products. The company focuses on developing intelligent chassis core components and chassis domain controllers, which are essential for modern vehicle systems. Additionally, Bebest offers technical services related to autonomous driving, as well as electronic mechanical brake systems and steering-by-wire systems. By providing high-quality solutions for chassis-by-wire technology, Bebest aims to meet the growing demands of the global automotive market.

Yaotan Pharmaceutical

Series A in 2022
Yaotan Pharmaceutical offers one-stop CDMO services for the research and production of raw materials and preparations CMC, covering the formulation process development, quality research, registration, and declaration of chemical raw materials and preparations, as well as for customers. They adhere to the unique concept and original aim of assisting the globe in the discovery and development of novel drugs. They are committed to establishing a service platform for small-molecule medication research and development.

MediLink Therapeutics

Series B in 2022
MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.

Bichen Pharmaceutical

Series B in 2022
Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.

TopOlefin Technology

Series A in 2022
TopOlefin Technology specializes in the research, development, and production of advanced polymer materials, with a focus on high-end optical resins. The company is dedicated to creating products characterized by high transparency, high refractive index, and strong gas barrier properties. These innovative materials find applications across various industries, including optical lenses, medical packaging, and consumer packaging. By prioritizing green and intelligent design, TopOlefin Technology aims to deliver high-quality resin solutions that meet the diverse needs of its clients.

SparX Group

Series B in 2021
SparX Group is a biotech firm that develops innovative anticancer biologics through bispecific antibodies and drug conjugates.

Thousand Oaks Biopharmaceuticals

Venture Round in 2021
Thousand Oaks Biopharmaceuticals, Inc., established in 2017 and headquartered in Haimen, China, specializes in contract development and manufacturing services for the biotechnology industry. The company focuses on developing technologies to produce protein and vaccine compounds, offering integrated control solutions that optimize processes, increase protein expression, and reduce production scale. Thousand Oaks provides personalized, chemically defined cell culture media, formula production, technical support, and ancillary services to its clients in the biopharmaceutical sector.

ColorTech Bio

Series B in 2021
ColorTech Bio researches and develops precision molecular diagnostic equipment. It offers medical devices to improve biotechnology services and solutions. ColorTech Bio was founded in 2018 and is based in Suzhou, China.

Qinghui Liannuo

Seed Round in 2021
Qinghui Liannuo is a scientific and technological innovation enterprise that transforms Tsinghua University's achievements in the research and development and application of immunotherapy technology. Actively promote the development of the γδ-T cell immunotherapy industry. Committed to bringing good news to patients with refractory and recurrent solid tumors and hematomas.

Vision X

Series B in 2021
Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.

Inmagene Biopharmaceuticals

Series C in 2021
Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based biopharmaceutical company founded in 2019, specializing in the research and pre-clinical development of therapies for immunology-related diseases. The company focuses on creating innovative drug candidates that address unmet medical needs globally, employing a strategy known as "Borderless Innovation." Inmagene has developed a diverse pipeline, including IMG-020, a protein drug designed to target IL-17A, which utilizes a combination of Affibody's protein therapeutics platform and Albumod technology to enhance potency and extend half-life. In addition to IMG-020, the company boasts several clinical-stage assets and multiple preclinical candidates aimed at improving pharmacokinetic and pharmacodynamic properties, safety profiles, and dosing convenience for patients. With additional offices in Hangzhou and Beijing, Inmagene is dedicated to advancing drug development through cutting-edge technology and a commitment to global collaboration in the fight against immunological diseases.

Chongxing Chongwu

Series B in 2021
Chongxing Chongwu is a supplier of pet supplies.

Hope Medicine

Series B in 2021
Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.

Zonsen Peplib Biotech

Series A in 2021
Zonsen Peplib Biotech builds a peptide compound library and provides peptide drug discovery and development services for global pharmaceutical and biotech companies. The company's technology could compress the amino acid sequence information of about 500,000,000 peptides into 80,000 peptide compounds.

Abogen Biosciences

Series B in 2021
Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.

Artivila Therapeutics

Seed Round in 2021
Artivila Therapeutics is a pharmaceutical company established in 2018 and based in Shenzhen, China. The company specializes in biotechnology and is dedicated to improving patient outcomes through innovative drug discovery. Utilizing an AI-powered platform, Artivila focuses on developing new therapeutic solutions for neurodegenerative diseases, cancers, and autoimmune diseases. Its integrated approach aims to consistently and efficiently deliver first-in-class drug candidates, positioning Artivila at the forefront of pharmaceutical research and development.

Biotheus

Series D in 2021
Biotheus Inc. is a biotechnology company based in Zhuhai, China, established in 2018. The company specializes in the development of monoclonal antibodies, recombinant proteins, and peptide biopharmaceuticals, with a focus on treating malignant tumors and autoimmune diseases. Biotheus is dedicated to advancing innovative biologics through the discovery and commercialization of next-generation multispecific antibodies. Its research emphasizes the mechanisms of regulatory T cells and innate immunity, aiming to create more effective immunotherapy solutions for cancer and metabolic disorders.

Novast

Venture Round in 2021
Novast Holdings Ltd. is a multinational pharmaceutical company with operations in China and the United States, specializing in the research, development, and manufacture of FDA-inspected generic drugs. The company focuses on creating complex formulations that incorporate challenging active pharmaceutical ingredients (APIs) and offers product development services leveraging its expertise in novel technologies and drug delivery systems. Novast has established itself as a prominent player in the pharmaceutical industry in China, possessing unique capabilities in drug development, quality systems, and infrastructure. It collaborates with pharmaceutical and biotechnology companies to bring products to regulated markets, particularly the U.S. market, where it is recognized as a pioneer among Chinese companies selling pharmaceuticals locally. Novast also operates cGMP manufacturing facilities and has a management team experienced in securing numerous generic drug patents in the U.S., alongside independent research and development of innovative drug-delivery technologies.

Imago BioSciences

Series C in 2020
Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

Xingyun Group

Series C in 2020
Xingyun Group specializes in transforming the digital supply chain for consumer goods, offering comprehensive Direct-to-Consumer (DTC) services. The company employs whole-process SaaS tools to enhance the global commodity trade environment. Its Management Middle-end System Services Engine integrates industrial ecological resources, facilitating cost reduction and efficiency improvements through data utilization. Xingyun Group supports overseas consumer brands in entering the Chinese market while assisting Chinese brands in their global expansion efforts. The platform boasts nearly 160 cooperative and self-operated warehouses across 72 countries and one region, catering to over 350,000 online and offline retailers in China. Its product offerings include maternal and child supplies, beauty care, healthcare, digital products, clothing, and shoes, ensuring reliable and cost-effective purchasing solutions for domestic retailers.

Gaugene

Series A in 2020
Gaugene specializes in providing advanced hematology testing instruments, reagents, and services tailored for in vitro diagnostic (IVD) users. As a high-tech enterprise, it is backed by experienced professionals from prominent domestic IVD companies who possess expertise in leading-edge technologies. The company’s instruments are unique in China, featuring high-power flow lasers and high-sensitivity multi-color fluorescence detection systems. These innovations enable a wide range of applications, including hematology diagnosis, clinical diagnosis, and life science research. Gaugene's solutions support clinical diagnostics and flow cytometry technology, facilitating single-cell research, protein screening, and the discovery of new clinical indicators.

Soocas

Series C in 2020
Soocas (Shenzhen) Technology Co., Ltd., established in 2015, specializes in personal digital health care products, focusing on innovative solutions for oral hygiene and personal care. The company is well-known for its sonic electronic toothbrushes, particularly the flagship model X3, and also offers products like blow dryers and shaving razors, all designed to integrate seamlessly within the Xiaomi ecosystem. Soocas emphasizes research and development to create high-performance, intelligent products tailored to consumer needs. The team comprises experienced professionals from leading hardware companies, bringing extensive knowledge in product design and user experience. With a commitment to innovation and quality, Soocas aims to enhance personal health care through its advanced electronic products.

Hanyu Medical

Series D in 2020
Hanyu Medical is a pioneering company in the development, production, and sale of transcatheter mitral valve repair devices, focusing on innovative solutions for heart valve diseases. Its primary product, Valve Clamp, is an interventional device designed for minimally invasive treatment of mitral valve regurgitation. This device facilitates the closure of heart valves during operations, allowing surgeons to perform heart surgeries with reduced invasiveness. Hanyu Medical's commitment to advancing medical technology positions it as a significant player in the cardiovascular device market.

Novast

Venture Round in 2020
Novast Holdings Ltd. is a multinational pharmaceutical company with operations in China and the United States, specializing in the research, development, and manufacture of FDA-inspected generic drugs. The company focuses on creating complex formulations that incorporate challenging active pharmaceutical ingredients (APIs) and offers product development services leveraging its expertise in novel technologies and drug delivery systems. Novast has established itself as a prominent player in the pharmaceutical industry in China, possessing unique capabilities in drug development, quality systems, and infrastructure. It collaborates with pharmaceutical and biotechnology companies to bring products to regulated markets, particularly the U.S. market, where it is recognized as a pioneer among Chinese companies selling pharmaceuticals locally. Novast also operates cGMP manufacturing facilities and has a management team experienced in securing numerous generic drug patents in the U.S., alongside independent research and development of innovative drug-delivery technologies.

ChosenMed

Series B in 2020
ChosenMed is a healthcare company specializing in oncology precision medicine. It is dedicated to early tumor screening and companion diagnosis, aiming to improve patient outcomes in cancer care. The company develops products that address the early screening, prevention, and diagnosis of tumors. Additionally, ChosenMed provides guidance for targeted medication related to solid tumors and predicts the efficacy of tumor immunotherapy. By offering a comprehensive range of precision medical solutions and immunotherapy options, ChosenMed strives to enhance treatment effectiveness and support personalized patient care in oncology.

GenFleet Therapeutics

Series B in 2020
GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

4inLook

Venture Round in 2020
4inLook is a retail company based in Shanghai, China, specializing in color contact lenses. Founded in 2008, it operates over 300 specialty stores primarily located in shopping centers within first- and second-tier cities. The company offers more than 200 designs of color contact lenses targeted at women aged 18 to 30. In addition to its physical retail presence, 4inLook has expanded its operations online through platforms like Tmall, allowing customers to experience a seamless shopping experience. Consumers can place orders online, pick them up in-store, and make appointments for product trials, thereby enhancing their purchasing convenience.

Xinjunte

Series A in 2020
Xinjunte has focused on the research and development of intelligent medical devices for bone surgery, and is committed to providing more efficient and safe medical devices.

EnnovaBio

Series A in 2019
EnnovaBio is a Chinese pharmaceutical company that specializes in the development of targeted therapeutic drugs. The company focuses on creating innovative immunotherapy pharmaceuticals aimed at treating prevalent autoimmune diseases and brain glioma. By concentrating on both cancer and autoimmune conditions, EnnovaBio seeks to provide effective treatment options that enhance patient outcomes and support medical practitioners in their efforts to address complex health challenges. Through its research and development initiatives, EnnovaBio aims to advance the field of immunotherapy and contribute to improved healthcare solutions in China.

Genetron Health

Series D in 2019
Genetron Health is a leading precision medicine company specializing in oncology, with a strong focus on cancer molecular profiling. The company leverages advanced technologies in molecular biology and data science to enhance cancer treatment. Genetron Health offers comprehensive health management products covering all aspects of full-cycle cancer clinical treatment, including risk assessment, early screening, molecular pathology diagnosis, medication guidance, and prognosis monitoring. They provide reliable molecular clinical services and professional cancer genetic risk assessments for patients and high-risk individuals. With global genomics sequencing and bioinformatics platforms, research and development centers in North Carolina and Beijing, and clinical laboratories across major Chinese cities, Genetron Health aims to expand its sales network throughout China. The company is dedicated to serving both Chinese and global cancer patients with its expertise in cancer genomics and efficient clinical translation.

Suzhou Kintor Pharmaceuticals

Series D in 2019
Suzhou Kintor Pharmaceuticals is a biopharmaceutical company established in 2009, primarily engaged in the research and development of innovative drugs targeting various cancers and androgen receptor-related diseases. Headquartered in Suzhou, China, the company focuses on addressing significant unmet medical needs in conditions such as metastatic castration-resistant prostate cancer, breast cancer, and liver cancer, which collectively represent a substantial portion of the global cancer burden. Kintor's leading drug candidates include Proxalutamide, currently undergoing clinical trials for prostate and breast cancer, and Pyrilutamide, which targets androgenetic alopecia and acne vulgaris. The company also develops several other drug candidates, including ALK-1 for liver cancer and Detorsertib, a second-generation mTOR inhibitor for metastatic solid tumors. Kintor's extensive product pipeline is built on proprietary research and development, aiming to deliver both “best-in-class” and “first-in-class” therapeutic options to patients in need.

Verseau Therapeutics

Venture Round in 2019
Verseau Therapeutics, Inc. is focused on developing macrophage checkpoint modulators aimed at treating patients with cancer, as well as immune and inflammatory diseases. Founded in 2017 and based in Lexington, Massachusetts, the company is creating a new class of therapeutics that target macrophages, which are crucial cells in the immune system. By shifting these cells between immune activators and silencers, Verseau's therapies aim to enhance the body's ability to mount an effective immune response against tumors. This innovative approach seeks to improve the efficacy of existing immunotherapies, offering new hope for patients facing challenging health conditions.

Julikang

Series B in 2019
Julikang is a third-party medical device disinfection service provider focused on the healthcare industry in China. The company offers disinfection services to numerous hospitals, utilizing automated cleaning devices to ensure thorough sanitation of items and areas. By interfacing with hospital information systems, Julikang implements sterile item traceability management software, which enhances the management of sterile articles. This integration allows real-time access to physical parameter information of medical devices, ensuring efficient traceability and compliance with hygiene standards. Through its services, Julikang aims to deliver professional quality sterilization and disinfection solutions to healthcare enterprises.

Loving Care

Series B in 2019
Loving Care International Pet Hospital is a comprehensive animal medical institution that operates a chain of clinics and hospitals focused on pet healthcare services. The facility offers a range of services including beauty treatments, physical examinations, vaccinations, and clinics. In addition to standard medical care, Loving Care provides users with information on the prevention of common diseases in dogs and cats, as well as alternative pet health issues. The establishment also operates mobile animal service vehicles to deliver home-based basic medical services, ensuring that pets receive the care they need in a convenient manner. Through its commitment to improving the diagnosis and treatment of pet diseases, including serious conditions such as tumors, Loving Care aims to enhance the overall well-being of animals and support pet owners in maintaining their pets' health.

ONLY STEM

Series A in 2019
Angstrom STEM is a brand of Anglia Education Group, integrating the resources and achievements of science and technology education of Shanghai Jiaotong University, and introducing the technology experience model of the United States and Canada, innovatively opening up STEM entertainment and education, integrating scientific experiments, model construction, mechanical energy, robot construction With programming, 3D printing, mathematics, etc., and focusing on the application and innovation of the latest science and technology, we have established a complete scientific STEM curriculum system to promote the quality education of domestic children and build a leading high-end STEM education brand in China.

Bitwise

Series A in 2019
Bitwise is a specialized asset manager focused on cryptocurrency investments for individuals, investment managers, and institutions. The company provides a diverse range of investment solutions, including index funds, yield and alpha strategies, multi-strategy offerings, and separately managed accounts. Bitwise emphasizes the importance of security and liquidity, implementing modern protective measures for assets. Its platform is designed to facilitate rules-based exposure to the cryptocurrency market, helping clients navigate the complexities of digital assets while aligning with their investment objectives.

NewDoon

Series B in 2019
NewDoon is a research, development, and manufacturing company of life science products and solutions. It is a company that develops neuroscience products and solutions. They have developed wireless optogenetics systems, fiber photometry systems, and miniaturized fluorescence microscopy.

Cullgen

Series A in 2019
Cullgen Inc. is a biopharmaceutical company based in San Diego, California, founded in 2018. The company specializes in the development of innovative small molecule therapeutics aimed at treating diseases that currently lack effective therapeutic options, including cancer, inflammatory, and autoimmune diseases. Utilizing its proprietary uSMITE™ platform, Cullgen employs targeted protein degradation technology to selectively degrade disease-causing proteins, even those previously deemed undruggable. This approach enables the creation of first-in-class new chemical entities, providing scientists with novel methodologies for drug discovery and potentially transforming treatment paradigms for difficult-to-treat conditions.

Abiochem Biotechnology

Series A in 2019
Abiochem Biotechnology is a high-tech enterprise specializing in enzyme engineering and genetic engineering technologies. The company focuses on researching and developing biocatalytic and synthetic biology methods, which are applied to large-scale production across various sectors. Its innovations are utilized in pharmaceuticals, health care products, and pesticides, contributing to advancements in green chemistry. Abiochem Biotechnology offers customized genetic and enzyme engineering services, positioning itself as a provider of bio-intelligent manufacturing solutions for chemical and biological products.

Imago BioSciences

Series B in 2019
Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

Boholo

Seed Round in 2019
Boholo, founded in 2011 and based in Shanghai, China, offers a digital medical management solution that integrates various advanced technologies. Its platform includes services such as clinical case management, three-dimensional surgical modeling and planning, and a multimedia case database. By utilizing artificial intelligence and machine vision, Boholo's medical imaging tools generate precise 3D anatomical models that assist medical professionals in planning surgical procedures, thereby increasing the likelihood of successful outcomes. The company also provides a comprehensive service platform that facilitates communication among specialists worldwide, enhancing their ability to deliver quality care.

BrightGene

Venture Round in 2019
BrightGene Bio-Medical Technology Company is a biopharmaceutical firm based in Suzhou, China, specializing in the research, development, manufacturing, and commercialization of innovative medicines and high-quality generic active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The company has a diverse product pipeline that includes immuno-oncological agents, GLP-1 receptor agonists for type 2 diabetes, and antibody-drug conjugates aimed at treating solid tumors and brain cancers. Additionally, BrightGene develops a variety of treatments such as Eribulin, Trabectedin, and various macromolecules and cytotoxic payloads. Its product offerings span multiple therapeutic areas, including oncology, cardiology, infectious diseases, and immunology. Founded in 2001, BrightGene has positioned itself as a leader in small molecules and nucleotide drugs, focusing on advancing therapeutics across all stages of development.

GenFleet Therapeutics

Series A in 2018
GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

VCBeat

Series A in 2018
VCBeat is an online platform founded in 2014 and headquartered in Chongqing, China, that focuses on delivering news and industry research specifically within the healthcare sector. The company provides comprehensive media coverage, data, and resources aimed at healthcare professionals, investors, and the general public. Through its service platform, VCBeat offers brand communication and industry consulting services, supporting healthcare entrepreneurs with industry research and the integration of various industry resources. By focusing on the future development of the healthcare industry, VCBeat plays a vital role in disseminating critical information and insights to its audience.

ZQ Automotive

Angel Round in 2018
ZQ Automotive focuses on automotive electronics and human-machine voice interaction technology. The company develops intelligent voice-based hardware and software for automobile systems, allowing users to engage in voice-based interactions while driving. This technology provides various features, including in-car voice learning, maintenance booking during discounts, in-car payment options, and leisure and entertainment services. By integrating these functionalities, ZQ Automotive aims to enhance the driving experience, ensuring it is both safe and enjoyable for users.

Biotheus

Series A in 2018
Biotheus Inc. is a biotechnology company based in Zhuhai, China, established in 2018. The company specializes in the development of monoclonal antibodies, recombinant proteins, and peptide biopharmaceuticals, with a focus on treating malignant tumors and autoimmune diseases. Biotheus is dedicated to advancing innovative biologics through the discovery and commercialization of next-generation multispecific antibodies. Its research emphasizes the mechanisms of regulatory T cells and innate immunity, aiming to create more effective immunotherapy solutions for cancer and metabolic disorders.

Maló Clinic

Series D in 2018
MALO CLINIC was established in 1995 by Dr. Paulo Malo. Today is world’s leader in Implantology and Dental Cosmetic as well as an Educational Centre on Oral Rehabilitation that trains over 3,500 professionals coming from all over the world per year. Besides Dentistry MALO CLINIC expanded to other health specialties, projecting an innovative concept of Medical Spa through a strong bet in wellbeing which resulted in the foundation of a Health Management business group spread worldwide known as MALO CLINIC Health & Wellness.

Predicine Huidu Medical Technology

Series A in 2018
Predicine Huidu Medical Technology Co., Ltd. is located in Fengxian, China, and specializes in the research and development of innovative technologies in the healthcare sector. The company focuses on gene detection methods and bioinformatics algorithms specifically designed for cancer diagnosis and monitoring. By creating a clinical application platform, Predicine Huidu Medical Technology connects patients with healthcare companies, facilitating advancements in tumor diagnosis and treatment. Through its technological offerings, the company aims to enhance the accuracy and effectiveness of cancer care.

Chemclin

Private Equity Round in 2018
Chemclin Biotech is a Chinese technical service provider specializing in in-vitro diagnostic instruments and auxiliary reagents for clinical diagnosis. The company develops, produces, and sells clinical immunochemiluminescence diagnostic testing reagents and instruments. Its services encompass a range of clinical inspection instruments, including chemiluminescence and biochemical reagents, as well as technical support, management, and certification. Additionally, Chemclin operates independent medical laboratories and is focused on introducing innovative diagnostic products and services to the Chinese market.

Gaugene

Angel Round in 2018
Gaugene specializes in providing advanced hematology testing instruments, reagents, and services tailored for in vitro diagnostic (IVD) users. As a high-tech enterprise, it is backed by experienced professionals from prominent domestic IVD companies who possess expertise in leading-edge technologies. The company’s instruments are unique in China, featuring high-power flow lasers and high-sensitivity multi-color fluorescence detection systems. These innovations enable a wide range of applications, including hematology diagnosis, clinical diagnosis, and life science research. Gaugene's solutions support clinical diagnostics and flow cytometry technology, facilitating single-cell research, protein screening, and the discovery of new clinical indicators.

Chowsing Live

Series A in 2018
Chowsing Live is an online retailer based in Shanghai, China, specializing in pet products and accessories. The company offers a range of items, including pet jumbo wipes, cat collars with bells, and flushable cat litters. Chowsing Live focuses on promoting design and creativity in its product development, aiming to address the genuine needs of pets and their owners. By providing innovative solutions, the company strives to foster a natural and harmonious lifestyle for both pets and pet-raising families.

MoonBiotech

Seed Round in 2018
MoonBiotech is a biotechnology company focused on the commercialization of microbial resources.

ChosenMed

Series A in 2018
ChosenMed is a healthcare company specializing in oncology precision medicine. It is dedicated to early tumor screening and companion diagnosis, aiming to improve patient outcomes in cancer care. The company develops products that address the early screening, prevention, and diagnosis of tumors. Additionally, ChosenMed provides guidance for targeted medication related to solid tumors and predicts the efficacy of tumor immunotherapy. By offering a comprehensive range of precision medical solutions and immunotherapy options, ChosenMed strives to enhance treatment effectiveness and support personalized patient care in oncology.

GenFleet Therapeutics

Seed Round in 2018
GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Kunya Medical

Series B in 2018
Kunya Medical is a provider of medical equipment management services focused on enhancing the maintenance and operational efficiency of hospital equipment. The company offers comprehensive services, including the maintenance and hosting of hospital imaging and radiation equipment, as well as installation, debugging, and repair of large and medium-sized medical devices. Kunya Medical also supplies spare parts and management software, facilitating improved oversight and longevity of clinical medical equipment for hospitals. By outsourcing these critical functions, Kunya Medical aims to help healthcare facilities optimize their equipment management and extend the lifecycle of their medical assets.

Junhetang

Series C in 2018
Junhetang operates a network of traditional Chinese medicine (TCM) clinics, providing a range of healthcare services that include herbal medicine, acupuncture, massage, exercise, and dietary therapies. The company combines TCM culture with the expertise of renowned TCM practitioners to deliver personalized medical services. Additionally, Junhetang integrates modern internet services into its offerings, creating an innovative TCM service network that encompasses education, training, medical care, and health maintenance. Headquartered in Nanjing, the company is actively expanding its presence in several major cities across China, including Shanghai, Shenzhen, Chengdu, and Taiyuan.

Chongxing Chongwu

Series A in 2018
Chongxing Chongwu is a supplier of pet supplies.

Suzhou Kintor Pharmaceuticals

Series C in 2018
Suzhou Kintor Pharmaceuticals is a biopharmaceutical company established in 2009, primarily engaged in the research and development of innovative drugs targeting various cancers and androgen receptor-related diseases. Headquartered in Suzhou, China, the company focuses on addressing significant unmet medical needs in conditions such as metastatic castration-resistant prostate cancer, breast cancer, and liver cancer, which collectively represent a substantial portion of the global cancer burden. Kintor's leading drug candidates include Proxalutamide, currently undergoing clinical trials for prostate and breast cancer, and Pyrilutamide, which targets androgenetic alopecia and acne vulgaris. The company also develops several other drug candidates, including ALK-1 for liver cancer and Detorsertib, a second-generation mTOR inhibitor for metastatic solid tumors. Kintor's extensive product pipeline is built on proprietary research and development, aiming to deliver both “best-in-class” and “first-in-class” therapeutic options to patients in need.

Sansure Biotech

Corporate Round in 2018
Sansure Biotech Inc. is a biotechnology company based in Changsha, Hunan Province, established in 2008. The company specializes in molecular diagnosis and genetic testing, developing and manufacturing a range of products that include nucleic acid extraction kits, real-time polymerase chain reaction (PCR) diagnostic kits, and fluorescence systems. Its product portfolio encompasses diagnostic kits for various health concerns, including novel coronavirus detection, viral hepatitis, AIDS, cancer biomarkers, and respiratory, digestive, and genetic diseases. Additionally, Sansure Biotech provides instruments and consumables to support its diagnostic offerings. The company primarily serves hospitals and laboratories both in China and internationally, focusing on enhancing diagnostic capabilities across multiple medical fields.

Loving Care

Angel Round in 2017
Loving Care International Pet Hospital is a comprehensive animal medical institution that operates a chain of clinics and hospitals focused on pet healthcare services. The facility offers a range of services including beauty treatments, physical examinations, vaccinations, and clinics. In addition to standard medical care, Loving Care provides users with information on the prevention of common diseases in dogs and cats, as well as alternative pet health issues. The establishment also operates mobile animal service vehicles to deliver home-based basic medical services, ensuring that pets receive the care they need in a convenient manner. Through its commitment to improving the diagnosis and treatment of pet diseases, including serious conditions such as tumors, Loving Care aims to enhance the overall well-being of animals and support pet owners in maintaining their pets' health.

EnnovaBio

Seed Round in 2017
EnnovaBio is a Chinese pharmaceutical company that specializes in the development of targeted therapeutic drugs. The company focuses on creating innovative immunotherapy pharmaceuticals aimed at treating prevalent autoimmune diseases and brain glioma. By concentrating on both cancer and autoimmune conditions, EnnovaBio seeks to provide effective treatment options that enhance patient outcomes and support medical practitioners in their efforts to address complex health challenges. Through its research and development initiatives, EnnovaBio aims to advance the field of immunotherapy and contribute to improved healthcare solutions in China.

WinnTi Medical

Series B in 2017
WinnTi Medical creates medical devices through continuous product innovations and manufacturing improvements, meeting surgeons' increasing demands, and improving patients' wellness.

General Healthy

Series A in 2017
General Healthy specializes in pharmaceutical logistics automation and mobile medical solutions. Based in Shanghai, the company offers products and services designed for the intelligent management of medicines, catering to both medical services and the pharmaceutical circulation industries. Through its innovative approach, General Healthy aims to enhance the efficiency and effectiveness of medicine management, addressing the needs of healthcare providers and pharmaceutical distributors.

Xiao Qu Hao Hushi

Series A in 2017
Xiao Qu Hao Hushi provides online medical consultancy services through an application.

Rundo Medical

Series B in 2017
Rundong Pharmaceutical R&D is a contract research organization (CRO) that focuses on clinical research outsourcing for pharmaceutical and biotechnology companies. It offers a comprehensive range of services, including clinical operations, medical data management, biostatistics, and medical project management. As a key player in the industry, Rundong is the main initiator and promoter of the China CRO Alliance, highlighting its leadership role in the field. The company has also achieved the distinction of being the first CRO in China to receive ISO 9001:2008 quality management system certification, demonstrating its commitment to high-quality standards in clinical research. Through its professional services, Rundong aims to support various companies in the pharmaceutical and biotech sectors in advancing their medical research initiatives.

Siyuans Aviation Tech

Angel Round in 2017
Siyuans Aviation Tech is a technology enterprise focused on the aerospace industry, specializing in the development and manufacturing of essential airport equipment. The company provides intelligent maintenance systems for airport navigation lights, along with integrated traffic control, runway lighting, and helicopter landing systems. Additionally, Siyuans offers fragile parts, integrated cabins, and multifunctional security wells designed for airport flight areas. By combining mechanical, electrical, control, and automation technologies, Siyuans aims to enhance airport operations through advanced solutions.

Cui Yutao Children Health Management Center

Series C in 2017
Cui Yutao Health Management Center specializes in the development of a comprehensive health management platform focused on children's physical and mental well-being. The center provides a mobile application that offers daily health records, an online parenting community, and expert guidance for child health management. It also facilitates access to medical assistance and child health insurance services. Through these offerings, parents can obtain valuable information related to childcare, including medical advice, early-stage education, and infant products, thereby enhancing pediatric care and supporting the health needs of children.

XANTHUS MEDIA

Angel Round in 2016
Xanthus Media is an animation production company. They involve in presenting audio-visual feasts and conveying emotional value. Screenwriting, designing, special effects, strategic consulting, management, and marketing are the business line of this company.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.